Breakthrough of poly(ADP-ribose) polymerase inhibitors (PARPi) resistance treating with the local therapy in recurrent epithelial ovarian cancer patients with oligo-progression

assessed both in vitro and in vivo can be used as a model to predict drug response of ovarian cancer.